St. Luke’s Hospital offering new prostate cancer imaging agent

UnityPoint Health - prostate cancer imaging agent Illuccix injection

UnityPoint Health – St. Luke’s Hospital Imaging/Nuclear Medicine Department is now offering the recent FDA approved prostate cancer imaging agent, Illuccix injection.

According to a news release, this new PET/CT imaging agent can aid clinicians in determining extent of disease in men with prostate cancer. St. Luke’s team imaged its first patient using the agent this week.

“We’re very excited to be able to offer this highly anticipated PET agent,” said Sarah Pauley, MD, PhD, medical director and radiation safety officer, Radiology Consultants of Iowa, PLC, in the release. “It is expected to transform imaging of and, ultimately treatment for prostate cancer.”

Illuccix is indicated for PET/CT imaging of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and suspected recurrence based on elevated serum prostate-specific antigen (PSA) level, according to the release.

It is anticipated that PSMA PET/CT imaging will replace body CT and bone scan as the standard of care. PSMA PET/CT imaging has been included in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for prostate cancer.

The imaging product received Food and Drug Administration (FDA) approval in December 2021.